Q-omics provides the consensus-scored PANK1 profile across patient tissues and cancer cell-line models. PANK1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PANK1 is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, PANK1 RNA expression shows 19,766 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KIRP, and LSCC as cancer lineages where PANK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PANK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PANK1 survival associations across molecular data types. PANK1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PANK1 RNA expression–survival associations across cancer types. High PANK1 expression shows unfavorable associations in ACC and SARC, but favorable associations in KIRC, LGG, GBM and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PANK1 RNA expression.
This table summarizes PANK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PANK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PANK1 shows lower tumor expression in KIRP, THCA, KICH, KIRC and LIHC and higher tumor expression in BLCA. The KIRP box plot shows higher PANK1 RNA expression in normal versus tumor tissue (log2 FC = −1.867, t-test p < 0.001).
This table shows molecular features associated with PANK1 in patient tissues and cancer cell lines. In patient samples, PANK1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PANK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
